Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:BYSI NASDAQ:CLNN NASDAQ:FLNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$13.40-9.6%$8.35$3.02▼$49.94$16.96M1.332.32 million shs112,732 shsBYSIBeyondSpring$1.57-4.8%$1.61$1.18▼$3.44$67.85M0.4324,960 shs14,427 shsCLNNClene$5.84+5.6%$6.28$3.25▼$13.50$70.66M0.91110,869 shs78,478 shsFLNACassava Sciences$1.25-4.6%$1.47$1.16▼$4.98$63.28M-0.71347,243 shs192,961 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+1.30%-6.44%+384.31%+61.65%-69.76%BYSIBeyondSpring0.00%-3.51%+18.71%-2.37%-43.30%CLNNClene+0.55%-4.98%-14.92%-3.32%+31.67%FLNACassava Sciences-0.76%-6.43%+9.17%-44.96%-37.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$13.40-9.6%$8.35$3.02▼$49.94$16.96M1.332.32 million shs112,732 shsBYSIBeyondSpring$1.57-4.8%$1.61$1.18▼$3.44$67.85M0.4324,960 shs14,427 shsCLNNClene$5.84+5.6%$6.28$3.25▼$13.50$70.66M0.91110,869 shs78,478 shsFLNACassava Sciences$1.25-4.6%$1.47$1.16▼$4.98$63.28M-0.71347,243 shs192,961 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics+1.30%-6.44%+384.31%+61.65%-69.76%BYSIBeyondSpring0.00%-3.51%+18.71%-2.37%-43.30%CLNNClene+0.55%-4.98%-14.92%-3.32%+31.67%FLNACassava Sciences-0.76%-6.43%+9.17%-44.96%-37.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.25Hold$89.00564.18% UpsideBYSIBeyondSpring 1.00SellN/AN/ACLNNClene 2.71Moderate Buy$33.25469.35% UpsideFLNACassava Sciences 2.00Hold$5.00300.00% UpsideCurrent Analyst Ratings BreakdownLatest AKTX, BYSI, FLNA, and CLNN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/14/2026CLNNClene Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/8/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/4/2026CLNNClene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.005/4/2026CLNNClene D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/22/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026AKTXAkari Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026AKTXAkari Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$24.75 per shareN/ABYSIBeyondSpring$1.75M36.89$0.11 per share14.52($0.59) per share-2.66CLNNClene$200K373.18N/AN/A($1.62) per share-3.60FLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$17.30MN/AN/AN/AN/AN/A-123.29%-63.01%8/18/2026 (Estimated)BYSIBeyondSpring-$1.01M-$0.14N/AN/AN/AN/AN/A-14.00%8/12/2026 (Estimated)CLNNClene-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/ALatest AKTX, BYSI, FLNA, and CLNN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026AKTXAkari Therapeutics-$1.33-$688.00-$686.67N/AN/AN/A5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/13/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05$8.77 millionN/A5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A3/30/2026Q4 2025AKTXAkari Therapeutics-$0.03-$2.68-$2.65-$2.6650N/AN/A3/25/2026Q4 2025BYSIBeyondSpring-$0.54-$0.05+$0.49-$0.05N/AN/A3/12/2026Q4 2025CLNNClene-$0.74-$0.88-$0.14-$0.88$0.03 million$0.08 million3/12/2026Q4 2025FLNACassava Sciences-$0.30-$0.26+$0.04-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABYSIBeyondSpringN/AN/AN/AN/AN/ACLNNCleneN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.270.27BYSIBeyondSpringN/A1.091.09CLNNCleneN/A1.941.93FLNACassava SciencesN/A2.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BYSIBeyondSpring40.29%CLNNClene23.28%FLNACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics32.20%BYSIBeyondSpring29.31%CLNNClene28.30%FLNACassava Sciences4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics91.14 million776,000Not OptionableBYSIBeyondSpring8041.12 million29.07 millionOptionableCLNNClene10012.78 million9.16 millionNo DataFLNACassava Sciences2048.31 million46.09 millionOptionableAKTX, BYSI, FLNA, and CLNN HeadlinesRecent News About These CompaniesCassava Sciences (NASDAQ:FLNA) and Madrigal Pharmaceuticals (NASDAQ:MDGL) Head to Head AnalysisJune 9 at 4:08 AM | americanbankingnews.comCassava Sciences (NASDAQ:FLNA) Lowered to Sell Rating by Wall Street ZenJune 6, 2026 | americanbankingnews.comData I/O And 2 Other Promising Penny Stocks To WatchMay 29, 2026 | finance.yahoo.comCassava Sciences and former execs, facing SEC charges for misleading claims, agree to finesMay 29, 2026 | statnews.comSFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | finance.yahoo.comFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | globenewswire.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | finance.yahoo.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | globenewswire.comFilana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | finance.yahoo.comFilana leaves Cassava roots behind amid branch into epilepsyMarch 11, 2026 | fiercepharma.comFCassava Sciences to rebrand to Filana TherapeuticsMarch 10, 2026 | seekingalpha.comCassava Sciences Announces Name Change to Filana Therapeutics, Inc.March 10, 2026 | finance.yahoo.comCassava Sciences Rebrands as Filana Therapeutics, Updates TickerMarch 10, 2026 | tipranks.comWhy Cassava Sciences, Inc.’s (SAVA) Stock Is Up 6.02%February 24, 2026 | aaii.comACassava says DoJ has ended probe into research misconductFebruary 20, 2026 | seekingalpha.comCassava Announces Closure of U.S. Department of Justice InvestigationFebruary 20, 2026 | finance.yahoo.comCassava Sciences stock rises after DOJ closes investigationFebruary 20, 2026 | za.investing.comCassava Sciences gains as DOJ ends probe into research misconduct claimsFebruary 20, 2026 | msn.comCassava Sciences says US DOJ has closed investigation into companyFebruary 20, 2026 | msn.comCassava Announces Closure of U.S. Department of Justice InvestigationFebruary 19, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKTX, BYSI, FLNA, and CLNN Company DescriptionsAkari Therapeutics NASDAQ:AKTX$13.40 -1.42 (-9.58%) Closing price 04:00 PM EasternExtended Trading$13.92 +0.51 (+3.84%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.BeyondSpring NASDAQ:BYSI$1.57 -0.08 (-4.85%) Closing price 04:00 PM EasternExtended Trading$1.60 +0.03 (+1.91%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Clene NASDAQ:CLNN$5.84 +0.31 (+5.61%) Closing price 04:00 PM EasternExtended Trading$5.86 +0.03 (+0.43%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Cassava Sciences NASDAQ:FLNA$1.25 -0.06 (-4.58%) As of 04:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
